Clinical Trials
9 trialsNCT07276386 2026-03-31
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07057596 2026-03-06
NEO-TB
Grupo Español Multidisciplinar de Melanoma
Phase 2 Recruiting
NCT06246149 2026-03-04
ATOM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT06070012 2026-02-27
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Recruiting
NCT05549297 2026-02-25
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Immunocore Ltd
Phase 3 Recruiting
NCT06627244 2026-02-23
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
University of Miami
Phase 2 Recruiting
NCT05315258 2025-07-17
TebeMRD
University of Oxford
Phase 2 Active not recruiting
NCT02535078 2024-07-24
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
Immunocore Ltd
Phase 1/2 Withdrawn
NCT02570308 2023-03-21
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Immunocore Ltd
Phase 1/2 Completed